Trial record 3 of 11 for:    Open Studies | "Hallux Valgus"

Pilot Study of CyclaPlex Implant, an Enhanced Suture and Button Implant Device in Hallux Valgus Deformity (CO001)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by Meir Medical Center
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01879150
First received: September 2, 2012
Last updated: June 13, 2013
Last verified: June 2013
  Purpose

Single center, open-label, single arm, pilot study designed to evaluate safety, tolerability and efficacy of CYCLAPLEX device, a minimal invasive enhanced suture and button implant and surgery tools for correction of inter-metatarsal angle in subjects suffering from mild to moderate Hallux Valgus deformity


Condition Intervention Phase
Hallux Valgus
Device: Cyclaplex bone anchor
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Single Center, Open-label, Single Arm, Study Designed to Evaluate Safety, Tolerability and Efficacy of CyclaPlex Implant and Tools for Correction of First Inter-metatarsal Angle in Subjects Suffering From Hallux Valgus Deformity

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • Percent of subjects with 1st IMA ≤9º or reduction of more than 7º in the 1st IMA compared to Base line at last observed value (LOV). [ Time Frame: 6 months follow up and 12 months follow up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • General Improvement as assessed by American Orthopaedic Foot and Ankle Society Hallux Metatarsophalangeal-lnterphalangeal Scale (AOFAS HMIS) score [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: Yes ]
    The AOFAS score results at each visit will be evaluated and compared to other known studies published

  • Pain and Functional assessment [Foot Function Index (FFI)] [ Time Frame: 6 months 12 months ] [ Designated as safety issue: Yes ]
    Pain and functional index will be assesed for complete results and separately for pain and functionality

  • Time to full weight bear, to use of regular shoes and fashion shoes. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Reduction in 1st IMA from baseline to LOV [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: No ]
  • Number and type of Adverse Events [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: Yes ]
    Adverse events will be evaluated for their severity and frequency

  • Complications at surgery [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Number and type of complications at surgery will be evaluated


Other Outcome Measures:
  • 1st intermetatarsal forces at time of implantation [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: June 2013
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CYCLAPLEX bone anchors

Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA >12degree, =<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia.

The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required.

Subjects will be followed-up for 50 weeks post-procedure.

Device: Cyclaplex bone anchor
Device implantation

Detailed Description:

INVESTIGATIONAL THERAPY Cycla Orthopedics Ltd has developed the CYCLAPLEX , a minimally invasive enhanced type of Suture and Button implant. It is intended to: (a) reduce the intermetatarsal angle (IMA) between 1MT and 2MT without osteotomy osteotomy b) reduce the risk of 2MT fractures (d) perform the implantation procedure in an easy and safe way.

The CYCLAPLEX predicated device is the "Suture and Button" type MiniTightrope. It is based on Mini Tightrope clinical experience, however with additional features to increase safety and functionality.

The CyclaPlex device comprise of two bone holders ('Anchors ') connected by a metal cord. The cord is connected to the buttons by crimp method as part of the surgery procedures The bone holders are T shape screws that are screwed into the bones after drilling holes across the 2 metatarsals. The gap in the bone as a result of the drilling is filled by the enhanced T shape buttons (screws). A nut is residing internally as part of the 1st met anchor structure. The IMA is reduced using specially designed tensioning tool CyclaPlex device is indicated for reducing intermetatarsal angles in cases where IMA is less than 200 eliminating the need for the traditional 1st metatarsal osteotomy. It used in conjunction with traditional release of the lateral MTP joint capsular structures and removal of the medial eminence as well as regular HVA reduction procedures such as AKIN.

The 2nd Metatarsal fracture risk is reduced due multiple/ accumulated factors:

(i) The hole drilled at 2nd metatarsal had been reduced significantly (ii) The hole is filled by conical screw and head. This firm anchoring method enable to distribute the horizontal forces applied during gate.

(iii) The metal screw type device enables bone growth over it and strengthen the bone at that area.

(iv) The connecting cord is housed inside the screw and has no direct touch with the bone, in both, 2nd and 1st metatarsals.

The device is delivered sterilized ( steam sterilization) double bag residing in cardboard box.

Dedicated assistive tools for multiple use are provided as well housed in a special tray intended for surgery room steam sterilization. The tools comprise of Aiming Drilling Guide,, screw driver for anchors insertion, Tensioning tool for reduction of the IMA, Crimping tool, cutter, single use drill bits

  Eligibility

Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Adult males and female subjects, aged 20 to 75 years old, inclusive, at screening visit
  • Subject weighing <100 kg and body mass index (BMI) <32 kg/m2
  • Subjects with confirm diagnosis of HV deformity based on radiography assessment of IMA > 12 º and less or equal to 20degree.
  • Subjects who would need osteotomy of the 1st MT as part of their surgery.
  • Able and willing to comply with the requirements of the protocol.
  • Able to understand and sign written informed consent to participate in the study

Exclusion criteria

  • Contraindication to implantation procedure
  • History of: Diabetes mellitus,Claudication vascular disease or known Peripheral Vascular Disease,Rheumatoid disease no palpable pulse (DP or PT),- Gout or any systemic inflammatory arthropathy,Osteoarthritis of first metatarsal,Neurological conditions associated with spasticity,No prior operation at 1st and 2nd Metatarsals
  • Osteoporosis
  • Secondary metatarsal complications including:Fracture (past or present), Aseptic necrosis or any deformity of 2nd MTH,Subject currently enrolled in or has not yet completed at least 30 days since ending
  • Any condition that may jeopardize study participation (e.g. abnormal clinical or laboratory finding), the interpretation of study results or may impede the ability to obtain informed consent (e.g., mental condition)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01879150

Locations
Israel
MMC Recruiting
Kfar Saba, Israel, 44281
Contact: Liraz Elazar    0509291083    Liraz.Elazar@clalit.org.il   
Contact: Elkahn Eleiv, MD    0545900119    'gibor5@gmail.com'   
Sub-Investigator: Victor Feldman, MD         
Sub-Investigator: Jonathan Koch, MD         
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: Elkahn Eliev, MD MMC orthopedic department physician
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01879150     History of Changes
Other Study ID Numbers: mmc-cyclaplex001-il
Study First Received: September 2, 2012
Last Updated: June 13, 2013
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Hallux Valgus
Foot Deformities
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on July 26, 2014